mihailgrey / iStockphoto.com
The US Court of Appeals for the Federal Circuit has ruled that a passing mention in the prior art of a formulation that references the claimed ingredient and administration may not be enough to invalidate a patent claim.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Impax, Lannett, AstraZeneca, Par, inter partes review, Zomig, nasal spray, patent infringement, patent invalidation, prior art, obviousness, generics